Project Grant R43HL187080
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $320K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
College Station, TX, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $894,314 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved prediction and mechanistic understanding of chronic obstructive pulmonary disease exacerbations by integrating multi-trait genetics, proteomics, and deep learning methods. The research comprises three specific aims. In Aim 1, the recipient will develop a multi-trait polygenic risk score integrating...
- The National Heart, Lung, and Blood Institute awarded Linshom Medical, Inc. $322,277 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct clinical evaluation of an alarm-activated detection system for early intervention of emerging respiratory decline using Linshom's FDA-cleared Continuous Predictive Respiratory Sensor (CPRS). The funding supports clinical development activities demonstrating the health economic value of the CPRS system, which...
- This $2,623,234 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports the development of a wearable multiplex biosensor system to monitor exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is the prime awardee, collaborating with researchers at the California Institute of Technology...
- The National Heart, Lung, and Blood Institute awarded $591,499 to Giner, Inc. on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, SBIR Phase I mechanism R43HL184803) to develop a portable, low-cost fractional exhaled nitric oxide (FeNO) breathalyzer for home-based asthma monitoring in children aged six and older. The device integrates a compact electrochemical nitric oxide sensor, humidity control module, and Bluetooth-enabled smartphone interface to enable...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $706,159 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a smart wearable continuous cuffless blood pressure, cardiac, and respiratory monitoring system agnostic to skin tone. The recipient will design and build an innovative wearable device integrating multiple non-invasive physiological sensors on the wrist to provide health-grade continuous...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $372,635 under NIH Project Grant R21HL188684 on August 15, 2026, to develop a network proximity-based drug repurposing pipeline for chronic obstructive pulmonary disease. The award funds two integrated aims. In Aim 1, the recipient will build an updated COPD disease module by integrating genome-wide association studies and multi-omics data into the human protein interactome, using a proximity-based...
- This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $274,274 to X-Cor Therapeutics Inc., a minority-owned small disadvantaged business in Washington, DC, to develop a novel respiratory dialysis system for treating chronic obstructive pulmonary disease (COPD) patients. The project aims to optimize a prototype that can efficiently remove excess carbon dioxide from the blood of COPD patients, with the goal of...
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded Arizona State University $233,854 on May 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop breath biomarkers for detecting Staphylococcus aureus lung infections in cystic fibrosis patients through secondary analysis of the IMPACT-BREATH clinical study data. The project addresses a clinical need: while highly effective cystic fibrosis transmembrane conductance regulator therapy has improved CF care, it has...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $268,500 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct multi-omic and network analysis investigating the role of X-linked transcription factors in chronic obstructive pulmonary disease heterogeneity. The research applies gene regulatory network analysis to multi-omic datasets from blood and lung tissue across four large COPD cohort studies (COPDGene, LTRC,...